University of Pennsylvania

Kollmorgen Corporation

Harvey Rubin

Barry S Cooperman

Zhi M Wang

Norman Schechter

Michael Plotnick

George J Todaro

Jeffrey Winkler

Neville Robert Kallenbach

Alison L Fisher

Robin M Hochstrasser

Takahiro Yano

Paul A Cornelius

Fude Yang

Norman Schecter

Sacha Kassovska-Bratinova

Jerome Salem

Sean Curran

Jiah Shin Teh

David Avarbock

The present invention includes a method of treating or preventing a disease or disorder such as a mycobacterial infection, a Gram-positive bacterium infection, a yeast infection, an inflammatory condition, an auto-immune disorder and/or a proliferative disorder in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one compound of the invention, which includes clofazimine derivatives.

Therapeutic agents

Nucleic acid molecules that encode R2 subunit protein and topoisomerase I protein, fragments thereof, recombinant expression vectors and host cells are disclosed. Oligonucleotide molecules with nucleotide sequences complimentary to a nucleotide sequence encode R2 subunit protein and topoisomerase I protein are disclosed.

Methods of identifying compounds that inhibit DNA synthesis in

A method of producing a recombinant serine protease inhibitor capable of effectively modulating serine protease activity is provided. Compositions capable of modulating serine protease activity and use of such compositions to regulate inflammatory processes in cells are also provided.

Methods for detecting genetic mutations resulting in protease inhibitor

The invention provides analogues of .alpha.-1-antichymotrypsin having amino acid substitutions at position 358. .alpha.-1-antichymotrypsin analogues having amino acid substitutions at positions 356-361 and analogues having amino acid substitutions at positions 356-361 wherein the amino acid at position 358 is substituted are also within the scope of the invention. These analogues exhibit chymase inhibitory activity. Also provided are novel .alpha.-1-antichymotrypsins having an N-terminal extension of methionine-alanine-serine or alanine-serine. Expression vectors for the production of .alpha.-1-antichymotrypsins are also provided. The present invention also provides host cells and cell cultures capable of expressing analogues of .alpha.-1-antichymotrypsin, as well as protein preparations from the host cells. Methods of producing and using the analogues of .alpha.-1-antichymotrypsin to inhibit chymase activity are also provided.

.alpha.-1-antichymotrypsin analogues having chymase inhibiting activity

The present invention provides an analogue of human .alpha.-1-antichymotrypsin wherein the amino acid at position 358 is selected from the group consisting of isoleucine, valine, alanine, aspattic acid, threonine, and glutamic acid.

.alpha.-1-antichymotrypsin analogues having elastase inhibitory activity

A method of producing a recombinant ACT analogs having modulated DNA binding capability is provided. Recombinant ACT analogs having modulated DNA binding capability are also provided.

Method of modulating DNA binding activity of recombinant .alpha.-1

Methods of producing effective recombinant serine protease inhibitors

This invention relates to the ribonucleotide reductase of Plasmodium falciparum (Pf RR), to the subunits of Pf RR (Pf R1 and Pf R2), and to compounds comprising peptides derived from the Pf R2 C-terminus sequence that inhibit the action of protozoal RR. The invention provides a method for the prevention and treatment of malaria caused by P. falciparum by controlling the proliferation of P. falciparum comprising administering to a patient at least one peptide according to the invention. Antimalarial compositions are provided which comprise a pharmaceutically acceptable carrier and at least one peptide according to the invention which inhibits the P. falciparum ribonucleotide reductase reduction of ribonucleotides to 2'-deoxyribonucleotides. Also provided are methods for diagnosing malaria and for screening potential antimalarial agents.

Plasmodium falciparum ribonucleotide reductase DNA

The invention provides .alpha.-1-antichymotrypsin and protein preparations comprising human .alpha.-1-antichymotrypsin produced by E. coli cells transformed with a DNA sequence encoding human .alpha.-1-antichymotrypsin. The invention also provides methods for producing .alpha.-1-antichymotrypsin. The invention further provides analogues of .alpha.-1-antichymotrypsin that exhibit antichymotrypsin, anti-trypsin and anti-thrombin activity and methods of producing the analogues.

.alpha.-1-antichymotrypsin, analogues and methods of production

A novel irradiation process and products made thereby. The process treats biological media such as blood fractions, genetically engineered protein products and vaccine preparations. The process photolyzes nucleic acids in preference to proteins in the media, e.g., it inactivates DNA- or RNA-containing pathogens while leaving the proteins substantially intact or functional. In general, the process comprises irradiating the medium with pulsed light of wavelength and flux selected so that (1) the nucleic acids in their ground state absorb radiation and thereby rise to an excited state or states, (2) the nucleic acids in their excited states absorb radiation and thereby rise to higher energy states and undergo photolysis, and (3) the proteins in their ground or their excited states do not absorb sufficient radiation to undergo substantial photolysis. It is surprising and unexpected that nucleic acids in their excited states undergo efficient photolysis whereas proteins under the same conditions in the same medium are kept substantially intact.

Growing community of inventors

Philadelphia, PA, United States of America

Harvey Rubin